Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
about
Kinase Inactive Tyrosine Kinase (Tyk2) Supports Differentiation of Brown Fat Cells.Type I interferon mimetics bypass vaccinia virus decoy receptor virulence factor for protection of mice against lethal infection.Short peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infectionsIn vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activityBeyond autophagy: New roles for ULK1 in immune signaling and interferon responses.Nuclear Localization of Suppressor of Cytokine Signaling-1 Regulates Local Immunity in the Lung.The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam's Broom?Noncanonical IFN Signaling: Mechanistic Linkage of Genetic and Epigenetic Events.Jun activation domain-binding protein 1 (JAB1) is required for the optimal response to interferons.IFN signaling: how a non-canonical model led to the development of IFN mimetics.
P2860
Q30275543-D79483DF-0D86-4A5C-8E0D-7CBF1D002308Q34057742-4E630236-F48D-4387-910B-4442D11E1717Q34293407-8FDC30A6-EF08-4D6B-9931-392F087695A4Q36107965-607BE15E-B0D9-4A1D-9871-F69D6E10F9E7Q36984702-1FEF68C7-6778-422C-8A06-636A7EF09577Q37421222-C1407761-8234-48FD-84D5-A9FA283AB7B3Q38177822-FFBE5FB0-2CA0-444A-91C0-32D58EDB1DEEQ39080509-83DCB95D-A1AA-4E9F-8D4E-668852C99412Q41817100-E480B8E5-538E-4C2F-96B8-07CF9E85F2CEQ42049778-8CDA281E-AEB8-4444-BFB8-8343EC3050CF
P2860
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@ast
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@en
type
label
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@ast
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@en
prefLabel
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@ast
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@en
P2093
P2860
P1476
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.
@en
P2093
Chulbul M Ahmed
Ezra N Noon-Song
Howard M Johnson
Kaisa Kemppainen
Massimo P Pascalli
P2860
P304
P356
10.1016/J.JNEUROIM.2012.10.006
P577
2012-10-27T00:00:00Z